Bogdan Iorga, Ph.D.

1998-2002 École Polytechnique, Palaiseau, Île-de-France, France 
 2002- ICSN CNRS, Paris, Île-de-France, France 
Computational chemistry, Drug design, Bioinformatics
"Bogdan Iorga"
Mean distance: (not calculated yet)


Sign in to add mentor
Philippe Savignac grad student 1998-2001 École Polytechnique
 (Synthèse d'alpha-monohalogénophosphonates par halogénation électrophile)
Jean-Marc Campagne post-doc 2002-2003 CNRS


Sign in to add trainee
Marie Varin grad student 2004-2007 Université Paris-Sud 11
François Martz grad student 2011-2014 Université Paris-Sud 11
Maria-Laura-Belén Dabos grad student 2015-2018 Université Paris-Saclay
Agustín Zavala grad student 2015-2018 Université Paris-Saclay
Eddy Elisée grad student 2016-2019 Université Paris-Saclay
Guillaume Bernadat post-doc 2009-2010 CNRS
Najette Amara post-doc 2011-2012 CNRS
Georgiana Surpateanu post-doc 2009-2013 CNRS
Claire Colas post-doc 2011-2013 CNRS
Cheickna Cissé post-doc 2012-2013 CNRS
Edithe Selwa post-doc 2013-2018 CNRS
Nawel Mele post-doc 2018-2019 CNRS
BETA: Related publications


You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect.

Denakpo E, Naas T, Iorga BI. (2023) An updated patent review of metallo-β-lactamase inhibitors (2020-2023). Expert Opinion On Therapeutic Patents. 33: 523-538
Gaillot S, Oueslati S, Vuillemenot JB, et al. (2023) Genomic characterization of an NDM-9-producing clinical isolate and role of Glu152Lys substitution in the enhanced cefiderocol hydrolysis of NDM-9. Frontiers in Microbiology. 14: 1253160
Dabos L, Raczynska JE, Bogaerts P, et al. (2023) Structural and Biochemical Features of OXA-517: a Carbapenem and Expanded-Spectrum Cephalosporin Hydrolyzing OXA-48 Variant. Antimicrobial Agents and Chemotherapy. e0109522
Dahdouh E, Allander L, Falgenhauer L, et al. (2022) Computational Modeling and Design of New Inhibitors of Carbapenemases: A Discussion from the EPIC Alliance Network. International Journal of Molecular Sciences. 23
Muntean MM, Muntean AA, Guerin F, et al. (2022) Optimization of the rapid carbapenem inactivation method for use with AmpC hyperproducers-authors' response. The Journal of Antimicrobial Chemotherapy
Jousset AB, Oueslati S, Emeraud C, et al. (2021) KPC-39-Mediated Resistance to Ceftazidime-Avibactam in a Klebsiella pneumoniae ST307 Clinical Isolate. Antimicrobial Agents and Chemotherapy. 65: e0116021
de Barsy M, Mercuri PS, Oueslati S, et al. (2021) Detection and characterization of VIM-52, a new variant of VIM-1 from clinical isolate. Antimicrobial Agents and Chemotherapy. AAC0266020
Muntean MM, Muntean AA, Guerin F, et al. (2021) Optimization of the rapid carbapenem inactivation method for use with AmpC hyperproducers. The Journal of Antimicrobial Chemotherapy
Rima M, Emeraud C, Bonnin RA, et al. (2021) Biochemical characterization of OXA-244, an emerging OXA-48 variant with reduced β-lactam hydrolytic activity. The Journal of Antimicrobial Chemotherapy
Romero E, Oueslati S, Benchekroun M, et al. (2021) Azetidinimines as a novel series of non-covalent broad-spectrum inhibitors of β-lactamases with submicromolar activities against carbapenemases KPC-2 (class A), NDM-1 (class B) and OXA-48 (class D). European Journal of Medicinal Chemistry. 219: 113418
See more...